Oppenheimer Sticks to Their Buy Rating for TherapeuticsMD (TXMD)

By Carrie Williams

Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (TXMDResearch Report) today and set a price target of $14. The company’s shares closed yesterday at $5.09.

Olson noted:

“TXMD reported 4Q results and launch progress for 2019 plans including Bijuva and Annovera launches. In 4Q there were 47.5K Imvexxy TRx’s dispensed to 22K patients at an average $219 WAC price implying a mix of 17.5% starter packs vs. 82.5% maintenance packs. Net Imvexxy sales were $0.9M due to copay assistance ahead of the end of the expected six-month payer block leading to a potential increase in net pricing in 1Q19. The Imvexxy launch trajectory is following Vagifem and is clearly separated from Osphena and Intrarosa. Bijuva launch is on track for 2Q19. TXMD reported 4Q EPS of $(0.17), in line with consensus. We update our model resulting in small changes to estimates. We reiterate our Outperform rating with details inside.”

According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.1% and a 34.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.

TherapeuticsMD has an analyst consensus of Moderate Buy, with a price target consensus of $20.50, representing a 302.8% upside. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.66 and a one-year low of $3.51. Currently, TherapeuticsMD has an average volume of 3.15M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.